Paxil Franchise In Peril After FDA Seizure
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's seizure of Paxil CR threatens about 90% of GlaxoSmithKline's remaining Paxil franchise sales in the U.S
You may also be interested in...
FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says
In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said
FDA Focus Will Be Phase IV Commitments Amidst "Safety Cloud," GSK Says
In light of the current "safety cloud," FDA may have an increasing focus on Phase IV commitments, GlaxoSmithKline said
FDA Seizure Of Paxil CR, Avandamet Follows GSK's Failure To Recall All Lots
GlaxoSmithKline's February recall involving the two drugs did not encompass all affected lots, FDA says in announcing seizure of all doses and lots of the products. The action follows two "Form 483" reports in the last two years for GSK's Cidra, Puerto Rico facility, where the antidepressant and antidiabetic drugs are manufactured.